dsm-firmenich launches Biond™ to advance biologics innovation

Kaiseraugst (Switzerland), Maastricht (The Netherlands), September 29, 2026 – dsm-firmenich announces the launch of Biond™ at CPHI Milan 2026—a dedicated portfolio of pharmaceutical-grade vitamins for biopharmaceutical applications.

Biond™: beyond ingredients, expertise designed for biologics manufacturing

Biologics manufacturing depends on healthy, productive cells. Vitamins play a critical role in the metabolic pathways that drive cell growth, viability, and protein expression, making their purity, consistency, and reliability essential to process performance. To support these demanding applications, dsm-firmenich has developed Biond™, a portfolio of high-purity vitamins specifically designed for cell culture media and biologics manufacturing.

Backed by decades of expertise in vitamin science, pharmaceutical-quality manufacturing, regulatory compliance, and sustainable production, Biond™ helps biopharmaceutical companies optimize cell culture performance, improve process consistency, and maximize productivity throughout development and commercial manufacturing. Supported by a global manufacturing footprint and resilient supply network, dsm-firmenich provides the quality assurance, technical expertise, and long-term supply reliability manufacturers need as biologics production continues to expand and evolve.

Commercialized in partnership with Brenntag Pharma

To ensure a seamless customer experience, dsm-firmenich’s Biond™ offering is available globally and exclusively through Brenntag’s biopharma product portfolio, BYPHAR.¹ The BYPHAR portal provides access to detailed product information, sample requests, and technical support via a trusted global biopharma distribution network.

“In biologics manufacturing, the performance of every raw material matters,” says Fernanda Onofre, Director, Global Marketing and Business Development—Pharma Biologics Solutions, dsm-firmenich. “Vitamins are essential to healthy cell growth and productivity, so manufacturers need confidence in their purity, quality, and consistency. That’s why we go beyond ingredients. With Biond™, we’re bringing our pharmaceutical experience directly to biologics manufacturers, backed by our trusted partnership with Brenntag Pharma and its established biopharma distribution network. Together, we’re giving customers worldwide the quality, expertise, and support they need today, with a strong foundation for long-term success as biopharma continues to evolve.”

Biond™ will make its debut at CPHI Milan 2026, taking place October 6–8. Visitors can meet dsm-firmenich experts in Excipients Hall 1, Stand 1B26, and Brenntag Pharma experts at Stand 1A26, to learn more about the portfolio and its applications in biologics manufacturing.

To learn more about Biond™, visit: www.dsm-firmenich.com/biond

About dsm-firmenich

As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for people and the planet. dsm-firmenich is a Swiss company, listed on the Euronext Amsterdam and SIX Swiss Exchange, with operations in almost 60 countries and revenues of more than €9 billion for its Continuing Operations following the divestment of Animal Nutrition & Health. With a diverse, worldwide team of nearly 21,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com